Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALL-4 Protocol: ALL-2 vs L-20 Induction for Adult ALL
NCT00002766Phase 3Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 1996
- Primary completion
- Sep 2011
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cytarabine and mitoxantrone in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL) and chronic myelogenous leukemia (CML) (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Complete Remission at 2 years. Started Mar 1996; status: completed.
02
Drugs
cytarabinemitoxantrone
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00002766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002766.